{"filing":{"accession_number":"0001193125-26-276065","cik":"0001770069","ticker":"MPLT","company_name":"MapLight Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"d227825d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526276065/d227825d8k.htm"},"events":[{"id":11967,"run_id":10530,"accession_number":"0001193125-26-276065","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Vishwas Setia's separation as Chief Financial Officer is the primary disclosed action, effective immediately following an HR violation review. While Jonathan Gillis's appointment as interim CFO is also disclosed, the filing centers on Setia's departure and the circumstances surrounding it (separation agreement, COBRA coverage). The CFO role is a named executive officer position material to investors' assessment of the company's financial leadership and governance.","company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8691,"accession_number":"0001193125-26-276065","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Vishwas Setia's separation as Chief Financial Officer is the primary disclosed action, effective immediately following an HR violation review. While Jonathan Gillis's appointment as interim CFO is also disclosed, the filing centers on Setia's departure and the circumstances surrounding it (separation agreement, COBRA coverage). The CFO role is a named executive officer position material to investors' assessment of the company's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:03:17.122144+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8691,"accession_number":"0001193125-26-276065","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Vishwas Setia's separation as Chief Financial Officer is the primary disclosed action, effective immediately following an HR violation review. While Jonathan Gillis's appointment as interim CFO is also disclosed, the filing centers on Setia's departure and the circumstances surrounding it (separation agreement, COBRA coverage). The CFO role is a named executive officer position material to investors' assessment of the company's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:03:17.122144+00:00","company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","filing_date":"2026-06-18"}]}